Rhythm Pharmaceuticals Inc stock PB Ratio (=61.48) is close to 1-year high of 61.48.
The historical rank and industry rank for Rhythm Pharmaceuticals's PB Ratio or its related term are showing as below:
MEX:RYTM'
s PB Ratio Range Over the Past 10 Years
Min: 0.69 Med: 7.82 Max: 367.92
Current: 61.48
During the past 11 years, Rhythm Pharmaceuticals's highest PB Ratio was 367.92. The lowest was 0.69. And the median was 7.82.
MEX:RYTM's PB Ratio is ranked worse than 98.05% of 1228
companies
in the Biotechnology industry
Industry Median: 2.95
vs MEX:RYTM: 61.48
During the past 12 months, Rhythm Pharmaceuticals's average Book Value Per Share Growth Rate was 502.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -23.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -28.70% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Rhythm Pharmaceuticals was -7.60% per year. The lowest was -60.50% per year. And the median was -10.35% per year.
Back to Basics: PB Ratio
Rhythm Pharmaceuticals (MEX:RYTM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rhythm Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Rhythm Pharmaceuticals (MEX:RYTM) has a PB Ratio of 57.65 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rhythm Pharmaceuticals and its competitors. This is 637% above median its historical median of 7.82. Over the past decade, Rhythm Pharmaceuticals' PB Ratio has ranged from 0.69 to 367.92. According to the industry distribution chart, Rhythm Pharmaceuticals ranks #1204 out of 1228 companies in the Biotechnology industry, placing it in the top 98%.
Is Rhythm Pharmaceuticals' PB Ratio too high?
Rhythm Pharmaceuticals' current PB Ratio of 57.65 is 637% above median its 10-year median of 7.82. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 367.92. The Biotechnology industry median PB Ratio is 2.95. Rhythm Pharmaceuticals' value of 57.65 is 1854.2% above this industry median. Based on the distribution chart, Rhythm Pharmaceuticals ranks #1204 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' PB Ratio compare to MIRM and SYRE?
According to the Biotechnology industry distribution chart, Rhythm Pharmaceuticals ranks #1204 out of 1228 companies for PB Ratio. This places Rhythm Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.95. Rhythm Pharmaceuticals' value of 57.65 is 1854.2% above this benchmark. Historically, Rhythm Pharmaceuticals' own PB Ratio has ranged from 0.69 to 367.92 over the past decade. While the company's 10-year median is 7.82 vs. the industry median of 2.95, Rhythm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Pharmaceuticals's current PB Ratio of 57.65 is 1854.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rhythm Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Pharmaceuticals's current PB Ratio is 57.65, which is 637% above median its own 10-year median of 7.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current PB Ratio of 57.65. The stock's GF Value™ is MXN1,874.87, compared to a current price of MXN1,866.76 — trading 0.4% below its estimated fair value. The current PB Ratio is 57.65, which is 637% above median its 10-year median of 7.82 and 1854.2% above the Biotechnology industry median of 2.95. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current PB Ratio is 57.65 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN1,866.76 is trading 0.4% below its estimated GF Value™ of MXN1,874.87.
Key valuation signals for MEX:RYTM:
PB Ratio: 57.65 (637% above median its 10-year median of 7.82)
GF Value™: MXN1,874.87 vs. price of MXN1,866.76 (0.4% below fair value)
Industry Position: 1854.2% above the Biotechnology median (#1204 of 1228)
No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score
Get the complete analysis for MEX:RYTM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RYTM has been successfully added to your 
